Targeting Perk in cancer therapy aims to disrupt the adaptive advantage that cancer cells gain from an active UPR. Perk inhibitors are being explored to reduce cancer cell viability and enhance the effectiveness of existing treatments like chemotherapy and radiation. By inhibiting Perk, the stress adaptation mechanisms within tumor cells can be weakened, leading to increased apoptosis and reduced tumor growth.
